Short Interest in Lantheus Holdings Inc (NASDAQ:LNTH) Drops By 8.2%

Lantheus Holdings Inc (NASDAQ:LNTH) saw a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 2,460,000 shares, a decrease of 8.2% from the April 30th total of 2,680,000 shares. Currently, 6.4% of the shares of the stock are short sold. Based on an average trading volume of 445,400 shares, the days-to-cover ratio is currently 5.5 days.

In other Lantheus news, Director Julie Mchugh sold 1,756 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $15.86, for a total value of $27,850.16. Following the completion of the sale, the director now directly owns 15,754 shares of the company’s stock, valued at approximately $249,858.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael P. Duffy sold 1,936 shares of the company’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $14.58, for a total transaction of $28,226.88. Following the completion of the sale, the senior vice president now directly owns 140,600 shares of the company’s stock, valued at $2,049,948. The disclosure for this sale can be found here. Insiders sold a total of 61,785 shares of company stock valued at $904,824 over the last three months. 2.08% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of LNTH. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Lantheus by 99.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,438 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 1,716 shares during the period. Meeder Asset Management Inc. increased its holdings in shares of Lantheus by 802.0% in the 4th quarter. Meeder Asset Management Inc. now owns 2,652 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 2,358 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Lantheus in the 4th quarter valued at about $57,000. Aigen Investment Management LP acquired a new position in shares of Lantheus in the 4th quarter valued at about $67,000. Finally, Pacer Advisors Inc. acquired a new position in shares of Lantheus in the 1st quarter valued at about $75,000. Institutional investors own 95.34% of the company’s stock.

Several analysts have issued reports on LNTH shares. BidaskClub downgraded Lantheus from a “hold” rating to a “sell” rating in a report on Friday, May 15th. ValuEngine upgraded Lantheus from a “sell” rating to a “hold” rating in a report on Saturday, February 15th.

NASDAQ LNTH traded up $0.06 on Friday, hitting $12.70. 167,995 shares of the company were exchanged, compared to its average volume of 318,262. The firm has a market capitalization of $502.52 million, a P/E ratio of 10.11 and a beta of 1.28. Lantheus has a twelve month low of $8.67 and a twelve month high of $29.80. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.91 and a quick ratio of 2.41. The company’s 50 day moving average price is $12.61 and its 200-day moving average price is $16.63.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.07. The company had revenue of $90.70 million for the quarter, compared to the consensus estimate of $91.70 million. Lantheus had a return on equity of 46.94% and a net margin of 7.13%. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.28 EPS.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Story: What does the Dogs of the Dow mean?

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.